Drug Importation
Commentary
Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives
Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Commentary
Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Drug Importation
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Blog
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Drug Importation
Sally Pipes – The World’s Medicine Chest
This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
340B
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
Commentary
A Year Later, Florida’s Drug Importation Plan Is Misguided As Ever
When president-elect Donald Trump joked about making Canada the 51st state, he had an unlikely supporter: Bernie Sanders. “Does that mean that we can adopt the Canadian health care system and . . . lower the cost of prescription drugs,” the Vermont senator wrote on X. “I’m all for it.” ...
Commentary
Drug price controls hurt patients
Costly Imported Medicines Leave Patients Vulnerable
Texas just became the latest state to look north for lower drug prices. As of the beginning of this month, the state’s Health and Human Services Commission gained authority to contract with Canadian wholesalers and suppliers to import prescription drugs from our northern neighbor. The prices of brand-name prescription drugs ...
Blog
The Fentanyl Resurgimiento— A Drug Like No Other
On January 11, 2023, Dr. Rahul Gupta, the Director of the White House Office of National Drug Control Policy (ONDCP) declared a small victory. He reported new figures from the Center for Disease Control estimating that nationally there was a 2.57 percent decrease in the number of fatal drug overdoses for ...
Commentary
Diversifying America’s supply chains point to a more prosperous economic future
Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Tying U.S. Drug Prices To Foreign Markets Risks Innovation And Lives
Earlier this month, President Donald Trump signed what he called “one of the most consequential Executive Orders in our Country’s history.” The order is essentially an updated version of his administration’s 2020 “Most Favored Nation” policy. It directs pharmaceutical companies to tie the U.S. prices of their drugs to the ...
Trump’s ‘Most Favored Nation’ Drug Plan Doesn’t Favor Americans
Last week, President Donald Trump revived one of the most ill-conceived health policy ideas of his first term. Via a new executive order, he’s directed his administration to deliver “most-favored-nation prescription drug pricing to American patients.” The idea is to bring other developed countries’ lower drug prices to the United ...
Pipes: “Imposing tariffs on pharmaceutical products and ingredients would be a grave mistake”
Click here to download a copy of Pipes’ comments Thank you for inviting public input on the Department’s Section 232 examination of pharmaceutical imports and their relevance to U.S. national security interests. As president and CEO of the Pacific Research Institute and a longtime healthcare policy analyst, I’ve spent over ...
Imposing Price Controls on U.S. Drugs Won’t Level the Playing Field
The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the process to develop a drug takes 10 years and only 12 percent of drugs make it to market. These costs do not change simply because governments impose price controls ...
Sally Pipes – The World’s Medicine Chest
This week, we present a special presentation of our recent webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores ...
Watch Webinar with Sally Pipes on her new book, “The World’s Medicine Chest”
Watch the webinar with Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy, discussing her new book, The World’s Medicine Chest: How America Achieved Pharmaceutical Supremacy – and How to Keep It (Encounter Books). The book explores how America became the world’s leader in biopharmaceutical ...
A Year Later, Florida’s Drug Importation Plan Is Misguided As Ever
When president-elect Donald Trump joked about making Canada the 51st state, he had an unlikely supporter: Bernie Sanders. “Does that mean that we can adopt the Canadian health care system and . . . lower the cost of prescription drugs,” the Vermont senator wrote on X. “I’m all for it.” ...
Drug price controls hurt patients
Costly Imported Medicines Leave Patients Vulnerable
Texas just became the latest state to look north for lower drug prices. As of the beginning of this month, the state’s Health and Human Services Commission gained authority to contract with Canadian wholesalers and suppliers to import prescription drugs from our northern neighbor. The prices of brand-name prescription drugs ...
The Fentanyl Resurgimiento— A Drug Like No Other
On January 11, 2023, Dr. Rahul Gupta, the Director of the White House Office of National Drug Control Policy (ONDCP) declared a small victory. He reported new figures from the Center for Disease Control estimating that nationally there was a 2.57 percent decrease in the number of fatal drug overdoses for ...
Diversifying America’s supply chains point to a more prosperous economic future
Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
